Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

Area of Science:

• Oncology
• Evolutionary Biology
• Computational Biology

Background:

• Drug resistance mediated by clonal evolution is a major challenge in cancer therapy.
• Evolutionary trade-offs, where resistance to one drug increases sensitivity to another, offer potential therapeutic targets.
• Experimental recapitulation of cancer evolutionary dynamics is difficult.

Purpose of the Study:

• To develop and demonstrate an experimental approach for 'evolutionary steering' to control tumor evolution and delay drug resistance.
• To investigate the mechanisms underlying evolved drug sensitivity.

Main Methods:

• Utilized single-cell barcoding for tracking cancer clones.
• Grew large cell populations (10^8-10^9) without re-plating to mimic in vivo conditions.
• Employed longitudinal, non-destructive monitoring of cancer clones.
• Integrated mathematical modeling of tumor evolution.

Main Results:

• Successfully demonstrated evolutionary steering in a lung cancer model.
• Showed that evolutionary steering favorably shifted tumor clonal composition.
• Observed collateral sensitivity and proliferative costs in evolved cancer clones.
• Identified genomic mechanisms driving evolved sensitivity.

Conclusions:

• The developed approach enables experimental modeling of evolutionary steering strategies.
• This method has the potential to control treatment resistance in cancer therapy.
• Understanding evolutionary trade-offs is crucial for developing effective cancer treatments.